Search research articles
Contact Us
Filters
Showing results (1-10 of 9) with videos related to
Page
of 1
Sort By:
Leukemia & Lymphoma
|
January 5, 2016
Clonal plasma cells keep strange company
Tomer M Mark, Karen Pekle
Leukemia & Lymphoma
|
April 11, 2003
BLT-D (clarithromycin [Biaxin], low-dose thalidomide, and dexamethasone) for the treatment of myeloma and Waldenström's macroglobulinemia
Morton Coleman, John Leonard, Larry Lyons, et al.
Blood
|
January 10, 2013
BiRd (clarithromycin, lenalidomide, dexamethasone): an update on long-term lenalidomide therapy in previously untreated patients with multiple myeloma
Adriana Rossi, Tomer Mark, David Jayabalan, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
October 21, 2017
Cellular Proliferation by Multiplex Immunohistochemistry Identifies High-Risk Multiple Myeloma in Newly Diagnosed, Treatment-Naive Patients
Scott Ely, Peter Forsberg, Ihsane Ouansafi, et al.
Leukemia & Lymphoma
|
December 11, 2007
Prophylactic low-dose aspirin is effective antithrombotic therapy for combination treatments of thalidomide or lenalidomide in myeloma
Ruben Niesvizky, Déborah Martínez-Baños, Jessica Jalbrzikowski, et al.
Leukemia & Lymphoma
|
March 1, 2014
Thalidomide, clarithromycin, lenalidomide and dexamethasone therapy in newly diagnosed, symptomatic multiple myeloma
Tomer M Mark, Isaac A Bowman, Adriana C Rossi, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
March 13, 2017
A Phase I Trial of High-Dose Lenalidomide and Melphalan as Conditioning for Autologous Stem Cell Transplantation in Relapsed or Refractory Multiple Myeloma
Tomer M Mark, Danielle Guarneri, Peter Forsberg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 30, 2013
Overcoming the response plateau in multiple myeloma: a novel bortezomib-based strategy for secondary induction and high-yield CD34+ stem cell mobilization
Ruben Niesvizky, Tomer M Mark, Maureen Ward, et al.
Blood
|
November 9, 2007
BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma
Ruben Niesvizky, David S Jayabalan, Paul J Christos, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 9) with videos related to
Sort By:
Page
of 1
Leukemia & Lymphoma
|
January 5, 2016
Clonal plasma cells keep strange company
Tomer M Mark, Karen Pekle
Leukemia & Lymphoma
|
April 11, 2003
BLT-D (clarithromycin [Biaxin], low-dose thalidomide, and dexamethasone) for the treatment of myeloma and Waldenström's macroglobulinemia
Morton Coleman, John Leonard, Larry Lyons, et al.
Blood
|
January 10, 2013
BiRd (clarithromycin, lenalidomide, dexamethasone): an update on long-term lenalidomide therapy in previously untreated patients with multiple myeloma
Adriana Rossi, Tomer Mark, David Jayabalan, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
October 21, 2017
Cellular Proliferation by Multiplex Immunohistochemistry Identifies High-Risk Multiple Myeloma in Newly Diagnosed, Treatment-Naive Patients
Scott Ely, Peter Forsberg, Ihsane Ouansafi, et al.
Leukemia & Lymphoma
|
December 11, 2007
Prophylactic low-dose aspirin is effective antithrombotic therapy for combination treatments of thalidomide or lenalidomide in myeloma
Ruben Niesvizky, Déborah Martínez-Baños, Jessica Jalbrzikowski, et al.
Leukemia & Lymphoma
|
March 1, 2014
Thalidomide, clarithromycin, lenalidomide and dexamethasone therapy in newly diagnosed, symptomatic multiple myeloma
Tomer M Mark, Isaac A Bowman, Adriana C Rossi, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
March 13, 2017
A Phase I Trial of High-Dose Lenalidomide and Melphalan as Conditioning for Autologous Stem Cell Transplantation in Relapsed or Refractory Multiple Myeloma
Tomer M Mark, Danielle Guarneri, Peter Forsberg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 30, 2013
Overcoming the response plateau in multiple myeloma: a novel bortezomib-based strategy for secondary induction and high-yield CD34+ stem cell mobilization
Ruben Niesvizky, Tomer M Mark, Maureen Ward, et al.
Blood
|
November 9, 2007
BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma
Ruben Niesvizky, David S Jayabalan, Paul J Christos, et al.
Page
of 1